This bill reclassifies pharmacy benefit managers (PBMs) as fiduciaries under federal law, requiring them to act in the best interest of group health plans they serve. It mandates PBMs to disclose all compensation sources (including rebates and fees) and prohibits them from shielding themselves from liability for breaches of duty. The law directly affects PBMs, employers offering health plans, and health insurers that use PBM services. Key provisions include new transparency rules, clarifying that PBMs cannot be the "responsible fiduciary" for disclosure purposes, and banning contracts that exempt PBMs from accountability.
This bill modifies how Medicare calculates rebates for certain drugs to potentially lower costs for beneficiaries. It changes the reference year for rebate calculations from 2021 back to 2016 for both Medicare Part B (outpatient drugs) and Part D (prescription drug coverage) programs. The bill also adjusts how drug units are counted for rebates, excluding units paid for through state Medicaid programs or other existing rebate programs. These changes apply to Part B rebates starting January 2026 and Part D rebates starting October 2025. The policy directly affects drug manufacturers who pay Medicare rebates and impacts Medicare beneficiaries through potential cost reductions in covered drugs.
HR 6575, the CommonGround for Affordable Health Care Act, extends enhanced premium tax credits for health insurance through 2026, directly benefiting millions of lower and middle-income Americans purchasing coverage through the ACA marketplace. The bill modifies income thresholds for premium subsidies, creating new income tiers that maintain or increase financial assistance for households earning up to 1,000% of the poverty level. It includes provisions to prevent fraud in health insurance exchanges by imposing civil penalties on agents and brokers who provide false information, and requires transparency in pharmacy benefit manager contracts to improve drug pricing accountability. The legislation also extends the annual open enrollment period for health insurance exchanges for the 2026 plan year, allowing more time for people to enroll or change coverage.
The PBM Disclosure Act clarifies that pharmacy benefit managers (PBMs) and third-party administrators (TPAs) must disclose both direct and indirect compensation they receive for managing pharmacy benefits in employer-sponsored health plans. This requirement directly affects PBMs and TPAs that provide pharmacy benefit management services to health plans. The bill mandates the Department of Labor to issue regulations within 180 days of enactment, which will apply to health plan years beginning six months after publication. The law explicitly clarifies an existing ERISA disclosure rule without creating new requirements.
The PILLS Act creates tax credits to encourage domestic production of generic drugs and biosimilars in the United States. It offers a production credit of 30% (increasing to 35% for final drug production) with an additional bonus for components made with U.S. materials, phasing out after 2033. The bill also provides a separate 25% investment credit for facilities building or expanding production of these drugs, ending for construction after December 31, 2028. To qualify, manufacturers must produce drugs in the U.S., meet FDA compliance requirements, and not be foreign entities of concern. These provisions primarily affect U.S.-based pharmaceutical companies producing generic drugs and biosimilars.
The End Price Gouging for Medications Act establishes annual reference prices for prescription drugs based on the lowest retail prices in 12 international reference countries (like Canada and the UK) or specific criteria if international data is unavailable. It requires drug manufacturers to sell medications at or below these reference prices for all patients covered by federal health programs - including Medicare, Medicaid, TRICARE, and VA care - as well as for all other patients, including those with private insurance. Manufacturers violating this rule face civil penalties of five times the revenue difference, with collected funds directed to the National Institutes of Health for drug research. This bill directly affects drug manufacturers and millions of Americans enrolled in the specified federal health programs.
This bill simplifies the approval process for biosimilar drugs - medicines that are highly similar to, but not identical to, existing biologic drugs. It amends the Public Health Service Act to clarify when biosimilars are deemed "interchangeable" with the original drug (allowing pharmacists to substitute them without a doctor's specific order), adjusts exclusivity periods for existing biosimilars, and sets a 60-day transition period after enactment. The bill also requires the FDA to update its guidance documents within 18 months to reflect these changes. This directly affects pharmaceutical companies developing biosimilars, the FDA in its review process, and ultimately patients seeking more affordable treatment options.
The MAPS Act requires the Secretary of Health and Human Services to update and maintain an Essential Medicines List including drugs critical for national security, public health emergencies, chronic conditions, and military readiness. It mandates annual risk assessments identifying supply chain vulnerabilities, particularly drugs sourced over 50% from high-risk foreign suppliers like China, and compiles data on manufacturing locations and shortages. The bill directs HHS to map U.S. pharmaceutical supply chains from raw materials to finished products, using data analytics to identify national security threats, and report findings annually to Congress. This directly affects federal agencies (HHS, Defense), drug manufacturers, and supply chain stakeholders through mandatory reporting and transparency requirements.
S 529, the Capping Prescription Costs Act of 2025, limits how much individuals and families must pay annually out-of-pocket for prescription drugs under most health insurance plans. Starting in 2026, it caps these costs at $2,000 per person or $4,000 per family per year, with automatic annual adjustments using the medical care inflation rate (CPI). This applies to both individual health plans (under the Affordable Care Act) and group health plans (like employer-sponsored coverage), as amended across multiple federal laws. The bill does not change drug prices but directly affects millions of health plan enrollees by setting a maximum annual cost for covered prescriptions.
This bill modernizes how the FDA inspects facilities manufacturing biosimilar drugs (similar but not identical versions of biologic medicines) in the U.S. It requires the FDA to hold a public meeting and issue a report on expanding international inspection agreements, update inspection tools to increase remote assessments (like virtual site reviews), and develop a strategic plan within a year to address staffing and communication challenges specific to biosimilar facility inspections. The bill directly affects FDA inspectors, biosimilar drug manufacturers, and the FDA's inspection processes for domestic facilities. It focuses on improving inspection efficiency and communication without changing drug approval standards or safety requirements.
